The emergence of bispecific antibodies (BsAbs) targeting T cells (CD3+) and tumor plasma B cells (BCMA+) has provided a new therapeutic option for patients with relapsed/refractory multiple myeloma cancer. However, responses to CD3×BCMA BsAb therapy remain heterogeneous, and treatment is associated with frequent immune...
Nicolas Deredec, Lisa Aziez, Ismael Boussaid et al.· bioRxiv· 0 citations
Low variant allele frequency (VAF) variants identified during germline testing may represent constitutional mosaicism or acquired somatic events restricted to hematopoietic cells. Although clonal hematopoiesis of indeterminate potential (CHIP) has emerged as an important source of interpretative pitfalls in hereditary...
A. Chansavang, C. Friedrich, Emmanuelle Kuhn et al.· European Journal of Endocrin...· 0 citations
Acute myeloid leukemia (AML) persistence and relapse are sustained by leukemia-propagating cells, yet the molecular programs supporting their expansion during disease evolution remain incompletely understood. Using serial patient-derived xenotransplantation, we establish a longitudinal model in which leukemia-initiatin...
Clément Larrue, Paolo Angelino, Sarah Mouche et al.· Cell Reports Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.